Oral α-secretase enhancers designed to prevent Aβ formation at every disease stage
Strengthening the brain's natural defence against amyloid
Protective by design
ADAM10 cuts APP in a way that prevents amyloid-β from forming and releases neurotrophic sAPPα.
Small Molecule
Designed as a once-daily pill for early and chronic treatment.
Genetically validated
Human genetics links mutations in ADAM10 to Alzheimer’s.
Alzheimer's begins decades before memories fade.
Early therapeutic intervention preserves what matters most.
Our goal
Treat Alzheimer's at its origin, prior clinical symptoms, with a therapy safe enough for long-term use.
From research to the clinic
AlphaSphere is a planned biotech Spin-off from the University of Basel
Accessible treatment
A simple oral pill instead of infusions and MRI monitoring, so treatment can reach more patients.
Founding Team
Advisory Board
Dr. Ulf Neumann
Drug DevelopmentDr. Lutz Wevelsiep
CMC & RegulatoryPartners & Supporters
Prof. Dr. Mike Recher
Scientific Co-Founder
mike.recher@usb.ch Prof. Dr. Rainer Riedl
Medicinal Chemistry, ZHAWProf. Dr. Stefan Lichtenthaler
Alpha-Secretase KOL, DZNE
Dr. Adrian Baldrich
Dr. Florian Marquardsen
CEO & Co-Founder
florian@alphasphere-therapeutics.comCSO & Co-Founder
adrian@alphasphere-therapeutics.comLet's talk
Investors, pharma partners, scientists or future colleagues: we look forward to hearing from you.